CLRB Maintained at Buy by Roth Capital, May 2026

Roth Capital maintained its Buy rating on Cellectar Biosciences (CLRB) on May 5, 2026, but cut the price target to $11 from $14. The biotech firm trades at $3.18 with a market cap of $10.2 million. Despite the target reduction, the analyst kept the CLRB rating maintained at Buy, signaling continued confidence in the company’s cancer drug pipeline. CLRB stock jumped 12.4% today on heavy volume. The company develops phospholipid drug conjugates for blood cancers and solid tumors.

CLRB Rating Maintained Despite Price Target Cut

Roth Capital’s Unchanged Buy Stance

Roth Capital kept its Buy rating on CLRB despite lowering the price target by $3 per share. The analyst maintained conviction in the company’s lead candidate, CLR 131, which is in Phase 2 trials for Waldenstrom’s macroglobulinemia and multiple myeloma. The price target reduction reflects near-term valuation pressures rather than clinical concerns. Roth Capital lowered the price target to $11 from $14, but the CLRB rating maintained at Buy shows the firm still sees upside potential. This is a common analyst move in biotech when clinical progress is solid but market conditions tighten.

Market Response and Stock Movement

CLRB stock surged 12.4% today to $3.18, defying the price target cut. Volume exploded to 54.3 million shares, nearly 1,556% above average. The stock trades well below the new $11 target, suggesting the market sees value at current levels. Year-to-date, CLRB is up 7.8%, though it remains down 60% over the past year. The company’s market cap sits at just $10.2 million, making it a micro-cap biotech play with significant execution risk.

Cellectar’s Pipeline and Clinical Progress

Lead Program CLR 131 in Multiple Trials

Cellectar’s flagship asset, CLR 131 (iopofosine I-131), is advancing through multiple clinical studies. The drug is in Phase 2 trials for relapsed or refractory Waldenstrom’s macroglobulinemia and B-cell malignancies. A separate Phase 2B study is underway in multiple myeloma patients. Phase 1 studies are also running in pediatric cancers, head and neck cancers, and relapsed/refractory myeloma. These parallel programs give the company multiple shots at regulatory approval and revenue generation.

Collaborative Development and Preclinical Work

Cellectar has partnered with multiple biotech firms to expand its phospholipid drug conjugate (PDC) platform. Collaborations include Avicenna Oncology for CLR 2000 Series, Orano Med for CLR 12120 Series, IntoCell Inc, and LegoChemBio. CLR 1900, a PDC chemotherapeutic program, remains in preclinical development for solid tumors. These partnerships reduce Cellectar’s development burden and provide potential revenue streams through milestone payments and royalties.

Financial Metrics and Meyka AI Grade

Meyka AI Rates CLRB with a Grade of B

Meyka AI rates CLRB with a grade of B, suggesting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company shows negative earnings with an EPS of -$8.35 and a PE ratio of -0.38. Cash per share stands at $3.11, providing runway for clinical trials. These grades are not guaranteed and we are not financial advisors.

Balance Sheet Strength and Cash Position

Cellectar maintains a strong current ratio of 2.96, indicating solid short-term liquidity. The company has minimal debt with a debt-to-equity ratio of just 0.04. Working capital totals $9.3 million, supporting ongoing R&D spending. However, the company burns cash with negative operating cash flow of -$5.45 per share. At current burn rates, Cellectar will need additional funding or clinical milestones to extend its runway beyond 2027.

Analyst Consensus and Market Outlook

Two Buy Ratings Drive Consensus

Two analysts currently rate CLRB as Buy, with no Hold or Sell ratings. This creates a consensus rating of 4.0 (Buy). The lack of bearish coverage suggests limited analyst attention on this micro-cap stock. Roth Capital’s maintained CLRB rating reflects the broader bullish view on the company’s pipeline potential. However, analyst coverage gaps can mean less scrutiny and higher volatility.

Price Forecasts and Technical Setup

Meyka AI’s AI-powered market analysis platform forecasts CLRB reaching $5.16 within one year and $12.96 within five years. The stock shows mixed technical signals with RSI at 62.5 (neutral) and MACD slightly negative. Money Flow Index is extremely overbought at 99.7, suggesting potential pullback risk after today’s rally. The stock trades between a 50-day average of $2.92 and a 200-day average of $3.78, indicating recent strength.

Final Thoughts

Roth Capital maintains a Buy rating on CLRB despite cutting its price target to $11, reflecting confidence in Cellectar’s cancer drug pipeline. CLR 131 is advancing through Phase 2 trials with multiple partnerships supporting the company’s prospects. However, the micro-cap faces execution risk due to its $10.2 million market cap and negative cash flow. The stock rallied 12.4% to $3.18, suggesting market value despite valuation pressures. Investors should monitor clinical data and funding announcements closely, as biotech volatility remains high.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.